2025年5月23日 周五
Home > Archive>Volume 31, Issue 7, 2023 >625-631
PDF HTML XML Export Cite reminder
Gut microbiota and immune regulation of cardiovascular diseases
Author:
Affiliation:

1.Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China;2.The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, Heilongjiang 150001, China;3.School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [63]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    Cardiovascular disease (CVD) has become the number one killer worldwide, and the morbidity and mortality significantly increased. Trillions of microorganisms inhabit the human gut and play crucial roles in metabolism, immunity and responses to diseases. Previous studies have demonstrated a correlation between cardiovascular diseases and gut microbiota. Both innate and adaptive immune mechanisms can affect the occurrence and development of cardiovascular diseases. The specific components and metabolites of gut microorganisms can regulate the differentiation and function of immune cells such as macrophages and lymphocytes, as well as influence the immune homeostasis through circulatory system. This review discusses the potential immune mechanisms between the gut microbiota and the development of cardiovascular diseases through the interaction of the gut microbiota and its metabolites with the immune system, which provides new insights into the prevention and treatment of cardiovascular diseases.

    Reference
    [1] ROTH G A, MENSAH G A, JOHNSON C O, et al.Global burden of cardiovascular diseases and risk factors, 1990—2019:update from the GBD 2019 study.J Am Coll Cardiol, 0,6(25):2982-3021.
    [2] RIDKER P M, EVERETT B M, THUREN T, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med, 7,7(12):1119-1131.
    [3] BRANDSMA E, KLOOSTERHUIS N J, KOSTER M, et al.A proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis.Circ Res, 9,4(1):94-100.
    [4] KASAHARA K, KRAUTKRAMER K A, ORG E, et al.Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model.Nat Microbiol, 8,3(12):1461-1471.
    [5] CLEMENTE J C, URSELL L K, PARFREY L W, et al.The impact of the gut microbiota on human health:an integrative view.Cell, 2,8(6):1258-1270.
    [6] LI J H, JIA H J, CAI X H, et al.An integrated catalog of reference genes in the human gut microbiome.Nat Biotechnol, 4,2(8):834-841.
    [7] 赵鹏, 刘新新, 田进伟.肠道菌群代谢物与心血管疾病关系的研究进展.中国动脉硬化杂志, 1,9(12):1094-1098.ZHAO P, LIU X X, TIAN J W.Research progress in the relationship between intestinal flora metabolites and cardiovascular disease.Chin J Arterioscler, 1,9(12):1094-1098.
    [8] HOOPER L V, LITTMAN D R, MACPHERSON A J.Interactions between the microbiota and the immune system.Science, 2,6(6086):1268-1273.
    [9] JIA W, LI H K, ZHAO L P, et al.Gut microbiota:a potential new territory for drug targeting.Nat Rev Drug Discov, 8,7(2):123-129.
    [10] QUIGLEY E M M.Gut bacteria in health and disease.Gastroenterol Hepatol (N Y), 3,9(9):560-569.
    [11] CUI L, ZHAO T T, HU H B, et al.Association study of gut flora in coronary heart disease through high-throughput sequencing.Biomed Res Int, 7,7:3796359.
    [12] VERHAAR B J H, COLLARD D, PRODAN A, et al.Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups:the HELIUS study.Eur Heart J, 0,1(44):4259-4267.
    [13] ZHOU C B, ZHOU Y L, FANG J Y.Gut microbiota in cancer immune response and immunotherapy.Trends Cancer, 1,7(7):647-660.
    [14] STOCKINGER B, OMENETTI S.The dichotomous nature of T helper 17 cells.Nat Rev Immunol, 7,7(9):535-544.
    [15] IVANOV II, ATARASHI K, Manel N, et al.Induction of intestinal Th17 cells by segmented filamentous bacteria.Cell, 9,9(3):485-498.
    [16] SMITH P M, HOWITT M R, PANIKOV N, et al.The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.Science, 3,1(6145):569-573.
    [17] ROUND J L, MAZMANIAN S K.Inducible Foxp3＋ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.Proc Natl Acad Sci U S A, 0,7(27):12204-12209.
    [18] BOTIA-SANCHEZ M, ALARCON-RIQUELME M E, GALICIA G.B cells and microbiota in autoimmunity .Int J Mol Sci, 1,2(9):4846.
    [19] ROSSER E C, OLEINIKA K, TONON S, et al.Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.Nat Med, 4,0(11):1334-1339.
    [20] ROUND J L, MAZMANIAN S K.The gut microbiota shapes intestinal immune responses during health and disease.Nat Rev Immunol, 9,9(5):313-323.
    [21] PLANER J D, PENG Y Q, KAU A L, et al.Development of the gut microbiota and mucosal IgA responses in twins and gnotobiotic mice.Nature, 6,4(7606):263-266.
    [22] ISHIZUKA I E, CHEA S, GUDJONSON H, et al.Single-cell analysis defines the divergence between the innate lymphoid cell lineage and lymphoid tissue-inducer cell lineage.Nat Immunol, 6,7(3):269-276.
    [23] VIVIER E, ARTIS D, COLONNA M, et al.Innate lymphoid cells:10 years on.Cell, 8,4(5):1054-1066.
    [24] SATOH-TAKAYAMA N, VOSSHENRICH C A J, LESJEAN-POTTIER S, et al.Microbial flora drives interleukin 22 production in intestinal NKp46＋ cells that provide innate mucosal immune defense.Immunity, 8,9(6):958-970.
    [25] BJRKEGREN J L M, LUSIS A J.Atherosclerosis:recent developments.Cell, 2,5(10):1630-1645.
    [26] ROY P, ORECCHIONI M, LEY K.How the immune system shapes atherosclerosis:roles of innate and adaptive immunity.Nat Rev Immunol, 2,2(4):251-265.
    [27] SAGE A P, TSIANTOULAS D, BINDER C J, et al.Functional role of B cells in atherosclerosis.Nat Rev Cardiol, 9,6(3):180-196.
    [28] GARSHICK M S, NIKAIN C, TAWIL M, et al.Reshaping of the gastrointestinal microbiome alters atherosclerotic plaque inflammation resolution in mice.Sci Rep, 1,1(1):8966.
    [29] MANCO M, PUTIGNANI L, BOTTAZZO G F.Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk.Endocr Rev, 0,1(6):817-844.
    [30] SHI W H, HUANG Y J, YANG Z, et al.Reduction of TMAO level enhances the stability of carotid atherosclerotic plaque through promoting macrophage M2 polarization and efferocytosis.Biosci Rep, 1,1(6):BSR20204250.
    [31] YOO J Y, SNIFFEN S, MCGILL PERCY K C, et al.Gut dysbiosis and immune system in atherosclerotic cardiovascular disease (ACVD).Microorganisms, 2,0(1):108.
    [32] PARATI G, GONCALVES A, SOERGEL D, et al.New perspectives for hypertension management:progress in methodological and technological developments.Eur J Prev Cardiol, 3,0(1):48-60.
    [33] CROWLEY S D, SONG Y S, LIN E E, et al.Lymphocyte responses exacerbate angiotensin Ⅱ-dependent hypertension.Am J Physiol Regul Integr Comp Physiol, 0,8(4):R1089-R1097.
    [34] CHAN C T, SOBEY C G, LIEU M, et al.Obligatory role for B cells in the development of angiotensin Ⅱ-dependent hypertension.Hypertension, 5,6(5):1023-1033.
    [35] TORAL M, ROBLES-VERA I, DE LA VISITACIN N, et al.Role of the immune system in vascular function and blood pressure control induced by faecal microbiota transplantation in rats.Acta Physiol (Oxf), 9,7(1):e13285.
    [36] WILCK N, MATUS M G, KEARNEY S M, et al.Salt-responsive gut commensal modulates TH17 axis and disease.Nature, 7,1(7682):585-589.
    [37] BARTOLOMAEUS H, BALOGH A, YAKOUB M, et al.Short-chain fatty acid propionate protects from hypertensive cardiovascular damage.Circulation, 9,9(11):1407-1421.
    [38] KIM S, GOEL R, KUMAR A, et al.Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure.Clin Sci (Lond), 8,2(6):701-718.
    [39] WANG L, ZHU Q, LU A H, et al.Sodium butyrate suppresses angiotensin Ⅱ-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin-angiotensin system.J Hypertens, 7,5(9):1899-1908.
    [40] HU Y F, CHEN Y J, LIN Y J, et al.Inflammation and the pathogenesis of atrial fibrillation.Nat Rev Cardiol, 5,2(4):230-243.
    [41] YAMASHITA T, SEKIGUCHI A, IWASAKI Y K, et al.Recruitment of immune cells across atrial endocardium in human atrial fibrillation.Circ J, 0,4(2):262-270.
    [42] LIU L, LEE J, FU G Q, et al.Activation of peripheral blood CD3＋ T-lymphocytes in patients with atrial fibrillation.Int Heart J, 2,3(4):221-224.
    [43] ZHANG Y, ZHANG S, LI B L, et al.Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome.Cardiovasc Res, 2,8(3):785-797.
    [44] SUN Z W, ZHOU D C, XIE X D, et al.Cross-talk between macrophages and atrial myocytes in atrial fibrillation.Basic Res Cardiol, 6,1(6):63.
    [45] ZUO K, LIU X Q, WANG P, et al.Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients.BMC Genomics, 0,1(1):526.
    [46] YU L L, MENG G N, HUANG B, et al.A potential relationship between gut microbes and atrial fibrillation:trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation.Int J Cardiol, 8,5:92-98.
    [47] ZHANG Y, BAUERSACHS J, LANGER H F.Immune mechanisms in heart failure.Eur J Heart Fail, 7,9(11):1379-1389.
    [48] SAGER H B, HULSMANS M, LAVINE K J, et al.Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure.Circ Res, 6,9(7):853-864.
    [49] BANSAL S S, ISMAHIL M A, GOEL M, et al.Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure.Circ Heart Fail, 7,0(3):e003688.
    [50] ANKER S D, EGERER K R, VOLK H D, et al.Elevated soluble CD14 receptors and altered cytokines in chronic heart failure.Am J Cardiol, 7,9(10):1426-1430.
    [51] CONRAADS V M, JORENS P G, DE CLERCK L S, et al.Selective intestinal decontamination in advanced chronic heart failure:a pilot trial.Eur J Heart Fail, 4,6(4):483-491.
    [52] BRANCHEREAU M, BURCELIN R, HEYMES C.The gut microbiome and heart failure:a better gut for a better heart.Rev Endocr Metab Disord, 9,0(4):407-414.
    [53] TANG T T, YUAN J, ZHU Z F, et al.Regulatory T cells ameliorate cardiac remodeling after myocardial infarction.Basic Res Cardiol, 2,7(1):232.
    [54] LEVY M, KOLODZIEJCZYK A A, THAISS C A, et al.Dysbiosis and the immune system.Nat Rev Immunol, 7,7(4):219-232.
    [55] CAMMAROTA G, IANIRO G, TILG H, et al.European consensus conference on faecal microbiota transplantation in clinical practice.Gut, 7,6(4):569-580.
    [56] SUEZ J, ZMORA N, ZILBERMAN-SCHAPIRA G, et al.Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT.Cell, 8,4(6):1406-1423.
    [57] SCHWAN A, SJLIN S, TROTTESTAM U, et al.Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces.Lancet, 3,2(8354):845.
    [58] COSTELLO S P, HUGHES P A, WATERS O, et al.Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis:a randomized clinical trial.JAMA, 9,1(2):156-164.
    [59] ZHENG M L, ZHOU W H, HUANG C C, et al.A single-cell map of peripheral alterations after FMT treatment in patients with systemic lupus erythematosus.J Autoimmun, 3,5:102989.
    [60] ZHANG S, DENG F Y, CHEN J X, et al.Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes:a systematic review.Front Cell Infect Microbiol, 2,2:1075201.
    [61] HOU K J, WU Z X, CHEN X Y, et al.Microbiota in health and diseases.Signal Transduct Target Ther, 2,7(1):135.
    [62] WANG Y H, WIESNOSKI D H, HELMINK B A, et al.Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.Nat Med, 8,4(12):1804-1808.
    [63] KIM E S, YOON B H, LEE S M, et al.Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-related protein 9 genetic deficiency.Exp Mol Med, 2,4(2):103-114.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

NI Wenjun, WANG Xueyu, ZHONG Shan, ZHAO Peng, ZHANG Jian, TIAN Jinwei. Gut microbiota and immune regulation of cardiovascular diseases[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2023,31(7):625-631.

Copy
Share
Article Metrics
  • Abstract:149
  • PDF: 493
  • HTML: 0
  • Cited by: 0
History
  • Received:November 03,2022
  • Revised:March 11,2023
  • Online: September 01,2023
Article QR Code

You are the 48168 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025